ECSP099330A - Compuesto de indol - Google Patents
Compuesto de indolInfo
- Publication number
- ECSP099330A ECSP099330A EC2009009330A ECSP099330A ECSP099330A EC SP099330 A ECSP099330 A EC SP099330A EC 2009009330 A EC2009009330 A EC 2009009330A EC SP099330 A ECSP099330 A EC SP099330A EC SP099330 A ECSP099330 A EC SP099330A
- Authority
- EC
- Ecuador
- Prior art keywords
- present
- glucokinase activator
- indol compound
- agent
- compound
- Prior art date
Links
- -1 INDOL COMPOUND Chemical class 0.000 title 1
- 229940124828 glucokinase activator Drugs 0.000 abstract 2
- 208000008589 Obesity Diseases 0.000 abstract 1
- 239000003795 chemical substances by application Substances 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 206010012601 diabetes mellitus Diseases 0.000 abstract 1
- 125000005843 halogen group Chemical group 0.000 abstract 1
- 125000004435 hydrogen atom Chemical group [H]* 0.000 abstract 1
- 235000020824 obesity Nutrition 0.000 abstract 1
- 239000008177 pharmaceutical agent Substances 0.000 abstract 1
- 229940002612 prodrug Drugs 0.000 abstract 1
- 239000000651 prodrug Substances 0.000 abstract 1
- 238000011321 prophylaxis Methods 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 238000011282 treatment Methods 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/433—Thidiazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Diabetes (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Epidemiology (AREA)
- Endocrinology (AREA)
- Emergency Medicine (AREA)
- Child & Adolescent Psychology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Indole Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2006285551 | 2006-10-19 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ECSP099330A true ECSP099330A (es) | 2009-06-30 |
Family
ID=39010108
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| EC2009009330A ECSP099330A (es) | 2006-10-19 | 2009-05-14 | Compuesto de indol |
Country Status (26)
| Country | Link |
|---|---|
| US (4) | US7652133B2 (enExample) |
| EP (2) | EP2074119A1 (enExample) |
| JP (1) | JP5260507B2 (enExample) |
| KR (1) | KR101444486B1 (enExample) |
| CN (1) | CN101573357B (enExample) |
| AU (1) | AU2007310064B2 (enExample) |
| BR (1) | BRPI0717722A2 (enExample) |
| CA (1) | CA2666973C (enExample) |
| CL (1) | CL2008001017A1 (enExample) |
| CR (1) | CR10748A (enExample) |
| EC (1) | ECSP099330A (enExample) |
| GE (1) | GEP20115241B (enExample) |
| IL (1) | IL198154A (enExample) |
| MA (1) | MA30890B1 (enExample) |
| ME (1) | MEP11809A (enExample) |
| MX (1) | MX2009003972A (enExample) |
| MY (1) | MY158052A (enExample) |
| NO (1) | NO20091948L (enExample) |
| NZ (1) | NZ576570A (enExample) |
| PE (1) | PE20090884A1 (enExample) |
| RU (1) | RU2454415C9 (enExample) |
| TN (1) | TN2009000129A1 (enExample) |
| TW (1) | TWI460176B (enExample) |
| UA (1) | UA97257C2 (enExample) |
| WO (1) | WO2008050821A1 (enExample) |
| ZA (1) | ZA200902585B (enExample) |
Families Citing this family (84)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MX2009011211A (es) * | 2007-04-16 | 2009-10-30 | Abbott Lab | Indoles sustituidos en la posicion 7 inhibidores de mci-1. |
| JPWO2008136428A1 (ja) | 2007-04-27 | 2010-07-29 | 武田薬品工業株式会社 | 含窒素５員複素環化合物 |
| EP2025674A1 (de) | 2007-08-15 | 2009-02-18 | sanofi-aventis | Substituierte Tetrahydronaphthaline, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel |
| EP2178870B1 (en) * | 2007-08-17 | 2018-09-19 | LG Chem, Ltd. | Indole and indazole compounds as an inhibitor of cellular necrosis |
| US20100267708A1 (en) * | 2007-12-20 | 2010-10-21 | Lg Life Sciences Ltd. | Glucokinase activators and pharmaceutical compositions containing the same as an active ingredient |
| KR101098583B1 (ko) * | 2008-01-04 | 2011-12-26 | 주식회사 엘지생명과학 | 세포, 조직 및 장기 보존 효과를 갖는 인돌 및 인다졸 유도체 |
| WO2009097995A1 (de) * | 2008-02-07 | 2009-08-13 | Sanofi-Aventis | Neue phenyl-substituierte imidazolidine, verfahren zu deren herstellung, diese verbindungen enthaltende arzneimittel und deren verwendung |
| AU2009234666B2 (en) | 2008-04-10 | 2014-02-20 | Takeda Pharmaceutical Company Limited | Fused ring compounds and use thereof |
| US8349886B2 (en) * | 2008-04-16 | 2013-01-08 | Takeda Pharmaceutical Company Limited | Nitrogenated 5-membered heterocyclic compound |
| AR072297A1 (es) * | 2008-06-27 | 2010-08-18 | Novartis Ag | Derivados de indol-2-il-piridin-3-ilo, composicion farmaceutica que los comprende y su uso en medicamentos para el tratamiento de enfermedades mediadas por la sintasa aldosterona. |
| JP5597200B2 (ja) * | 2008-08-18 | 2014-10-01 | プロメガ コーポレイション | ルミネッセンスを生じる化合物およびチトクロムｐ４５０３ａ酵素を検出するための方法 |
| AR073380A1 (es) | 2008-09-25 | 2010-11-03 | Takeda Pharmaceutical | Composicion farmaceutica solida. comprimido multicapa |
| JP5535931B2 (ja) | 2008-10-27 | 2014-07-02 | 武田薬品工業株式会社 | 二環性化合物 |
| US8557805B2 (en) | 2008-12-29 | 2013-10-15 | Takeda Pharmaceutical Company Limited | Fused ring compound and use thereof |
| EP2448921A4 (en) * | 2009-04-09 | 2013-01-23 | Msd Kk | ARYLINDOLDERIVATE |
| JP5657578B2 (ja) | 2009-06-09 | 2015-01-21 | 武田薬品工業株式会社 | 新規な縮合環化合物およびその用途 |
| EA201270204A1 (ru) | 2009-07-28 | 2012-08-30 | Такеда Фармасьютикал Компани Лимитед | Таблетка |
| WO2011107494A1 (de) | 2010-03-03 | 2011-09-09 | Sanofi | Neue aromatische glykosidderivate, diese verbindungen enthaltende arzneimittel und deren verwendung |
| BR112012027648A2 (pt) | 2010-04-27 | 2019-09-24 | Takeda Pharmaceuticals Co | composto medicamento, método para profilaxia ou tratamento de doença, e, uso de composto |
| CA2802483C (en) | 2010-06-16 | 2017-10-24 | Takeda Pharmaceutical Company Limited | Crystal of amide compound |
| WO2011159781A2 (en) * | 2010-06-17 | 2011-12-22 | Senomyx, Inc. | Bitter taste modulators |
| US8933024B2 (en) | 2010-06-18 | 2015-01-13 | Sanofi | Azolopyridin-3-one derivatives as inhibitors of lipases and phospholipases |
| US8530413B2 (en) | 2010-06-21 | 2013-09-10 | Sanofi | Heterocyclically substituted methoxyphenyl derivatives with an oxo group, processes for preparation thereof and use thereof as medicaments |
| TW201221505A (en) | 2010-07-05 | 2012-06-01 | Sanofi Sa | Aryloxyalkylene-substituted hydroxyphenylhexynoic acids, process for preparation thereof and use thereof as a medicament |
| TW201215387A (en) | 2010-07-05 | 2012-04-16 | Sanofi Aventis | Spirocyclically substituted 1,3-propane dioxide derivatives, processes for preparation thereof and use thereof as a medicament |
| TW201215388A (en) | 2010-07-05 | 2012-04-16 | Sanofi Sa | (2-aryloxyacetylamino)phenylpropionic acid derivatives, processes for preparation thereof and use thereof as medicaments |
| WO2012036293A1 (ja) | 2010-09-17 | 2012-03-22 | 武田薬品工業株式会社 | 糖尿病治療剤 |
| PE20140161A1 (es) | 2010-11-30 | 2014-02-19 | Takeda Pharmaceutical | Compuesto biciclico |
| EA201391180A1 (ru) | 2011-02-17 | 2014-01-30 | Такеда Фармасьютикал Компани Лимитед | Способ получения оптически активных производных дигидробензофурана |
| WO2013037390A1 (en) | 2011-09-12 | 2013-03-21 | Sanofi | 6-(4-hydroxy-phenyl)-3-styryl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors |
| WO2013045413A1 (en) | 2011-09-27 | 2013-04-04 | Sanofi | 6-(4-hydroxy-phenyl)-3-alkyl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors |
| JP6050238B2 (ja) * | 2011-10-19 | 2016-12-21 | 興和株式会社 | 新規なスピロインドリン化合物、及びそれを含有する医薬 |
| WO2013061962A1 (ja) | 2011-10-24 | 2013-05-02 | 武田薬品工業株式会社 | 二環性化合物 |
| US9365540B2 (en) | 2012-01-12 | 2016-06-14 | Takeda Pharmaceutical Company Limited | Benzimidazole derivatives as MCH receptor antagonists |
| EP2816032A4 (en) | 2012-02-13 | 2015-09-30 | Takeda Pharmaceutical | AROMATIC RING CONNECTION |
| JP6095580B2 (ja) | 2012-02-13 | 2017-03-15 | 武田薬品工業株式会社 | 芳香環化合物 |
| WO2013122260A1 (en) | 2012-02-15 | 2013-08-22 | Takeda Pharmaceutical Company Limited | Tablet |
| CA2864990C (en) | 2012-02-24 | 2021-03-02 | Nobuyuki Takakura | Benzofuran and benzothiophene compounds for the inhibition of ghrelin o-acyltranferase (goat) |
| CA2868713A1 (en) | 2012-03-29 | 2013-10-03 | Takeda Pharmaceutical Company Limited | Aromatic ring compound |
| US20150087628A1 (en) | 2012-04-10 | 2015-03-26 | The Regents Of The University Of California | Compositions and methods for treating cancer |
| JPWO2013168760A1 (ja) | 2012-05-10 | 2016-01-07 | 武田薬品工業株式会社 | 芳香環化合物 |
| US9440987B2 (en) | 2012-05-10 | 2016-09-13 | Takeda Pharmaceutical Company Limited | Aromatic ring compound |
| KR102145641B1 (ko) | 2012-06-05 | 2020-08-18 | 다케다 야쿠힌 고교 가부시키가이샤 | 고형 제제 |
| JP2015127299A (ja) | 2012-07-19 | 2015-07-09 | 武田薬品工業株式会社 | 固形製剤 |
| WO2014085486A2 (en) | 2012-11-30 | 2014-06-05 | Waters Technologies Corporation | Methods and apparatus for the analysis of vitamin d metabolites |
| ES2629729T3 (es) | 2013-03-14 | 2017-08-14 | Takeda Pharmaceutical Company Limited | Derivados de espiro azetidina asoxazol y uso de los mismos como antagonistas de sstr5 |
| US10005720B2 (en) | 2013-04-05 | 2018-06-26 | North Carolina Central University | Compounds useful for the treatment of metabolic disorders and synthesis of the same |
| UY35650A (es) | 2013-07-09 | 2015-02-27 | Takeda Pharmaceutical | Compuesto heterocíclico |
| WO2015020184A1 (ja) | 2013-08-09 | 2015-02-12 | 武田薬品工業株式会社 | 芳香環化合物 |
| ES2835851T3 (es) | 2013-08-22 | 2021-06-23 | Lg Chemical Ltd | Compuesto de indol amida como inhibidor de necrosis |
| JO3442B1 (ar) | 2013-10-07 | 2019-10-20 | Takeda Pharmaceuticals Co | مضادات ذات نوع فرعي من مستقبل سوماتوستاتين 5 (sstr5) |
| US9428470B2 (en) | 2014-02-13 | 2016-08-30 | Takeda Pharmaceutical Company Limited | Heterocyclic compound |
| US9346776B2 (en) | 2014-02-13 | 2016-05-24 | Takeda Pharmaceutical Company Limited | Fused heterocyclic compound |
| CN104098498A (zh) * | 2014-07-30 | 2014-10-15 | 天津市斯芬克司药物研发有限公司 | 一种吲唑类化合物及其制备方法 |
| JOP20180029A1 (ar) | 2017-03-30 | 2019-01-30 | Takeda Pharmaceuticals Co | مركب حلقي غير متجانس |
| JOP20180028A1 (ar) | 2017-03-31 | 2019-01-30 | Takeda Pharmaceuticals Co | مركب ببتيد |
| AR111199A1 (es) | 2017-03-31 | 2019-06-12 | Takeda Pharmaceuticals Co | Compuesto aromático agonista de gpr40 |
| JPWO2018181847A1 (ja) | 2017-03-31 | 2020-03-05 | 武田薬品工業株式会社 | 芳香環化合物 |
| UA129084C2 (uk) | 2018-03-23 | 2025-01-08 | Кармот Терап'Ютікс, Інк. | Модулятори спряжених з g-білком рецепторів |
| WO2020045326A1 (ja) | 2018-08-27 | 2020-03-05 | 株式会社スコヒアファーマ | 安息香酸エステル化合物 |
| WO2020067575A1 (en) | 2018-09-24 | 2020-04-02 | Takeda Pharmaceutical Company Limited | Gip receptor agonist peptide compounds and uses thereof |
| JP2022503793A (ja) | 2018-09-24 | 2022-01-12 | 武田薬品工業株式会社 | Ｇｉｐ受容体アゴニストペプチド化合物及びその使用 |
| CN109250963B (zh) * | 2018-09-29 | 2021-07-16 | 福建省昊立建设工程有限公司 | 一种复合增韧混凝土及其制备方法 |
| JP7711074B2 (ja) | 2020-02-07 | 2025-07-22 | ガシャーブラム・バイオ・インコーポレイテッド | ヘテロ環ｇｌｐ－１アゴニスト |
| PH12022552562A1 (en) | 2020-03-25 | 2022-12-19 | Takeda Pharmaceuticals Co | Qd dosing of gip receptor agonist peptide compounds and uses thereof |
| WO2021193983A2 (en) | 2020-03-25 | 2021-09-30 | Takeda Pharmaceutical Company Limited | Qw dosing of gip receptor agonist peptide compounds and uses thereof |
| CN113563306B (zh) * | 2020-04-28 | 2022-07-01 | 新发药业有限公司 | 一种2-(4-苯氧基苯基)-6-(哌啶-4-)基烟酰胺的制备方法 |
| KR20240007251A (ko) | 2021-05-13 | 2024-01-16 | 카모트 테라퓨틱스, 인크. | G-단백질 결합 수용체의 조절제 |
| EP4490155A1 (en) | 2022-03-09 | 2025-01-15 | Gasherbrum Bio, Inc. | Heterocyclic glp-1 agonists |
| WO2023179542A1 (en) | 2022-03-21 | 2023-09-28 | Gasherbrum Bio , Inc. | 5,8-dihydro-1,7-naphthyridine derivatives as glp-1 agonists for the treatment of diabetes |
| WO2023198140A1 (en) | 2022-04-14 | 2023-10-19 | Gasherbrum Bio, Inc. | Heterocyclic glp-1 agonists |
| CN121002014A (zh) | 2022-12-15 | 2025-11-21 | 加舒布鲁姆生物公司 | 具有glp-1激动剂活性的化合物的盐和固体形式 |
| CN120693338A (zh) | 2022-12-22 | 2025-09-23 | 加舒布鲁姆生物公司 | 杂环的glp-1激动剂 |
| CN120712261A (zh) | 2022-12-22 | 2025-09-26 | 加舒布鲁姆生物公司 | 杂环的glp-1激动剂 |
| KR20250168210A (ko) | 2023-02-16 | 2025-12-02 | 가셔브룸 바이오, 인크. | 헤테로시클릭 glp-1 효능제 |
| AU2024311208A1 (en) | 2023-06-30 | 2026-01-15 | Gasherbrum Bio, Inc. | Heterocyclic glp-1 agonists |
| AR133240A1 (es) | 2023-07-13 | 2025-09-10 | Aconcagua Bio Inc | Compuestos, composiciones y métodos |
| WO2025015269A1 (en) | 2023-07-13 | 2025-01-16 | Aconcagua Bio, Inc. | Compounds, compositions, and methods |
| WO2025045208A1 (en) | 2023-08-31 | 2025-03-06 | Gasherbrum Bio, Inc. | Heteroaryl-heterocycloalkyl-based glp-1 agonists |
| US20250188081A1 (en) * | 2023-12-08 | 2025-06-12 | Shaman Pharma, LLC | Method for Production of Spiro-Oxindole and Indoxyl Derivatives of Mitragynine |
| WO2025137307A1 (en) | 2023-12-20 | 2025-06-26 | Gasherbrum Bio, Inc. | Heterocyclic glp-1 agonists |
| WO2025154020A1 (en) | 2024-01-19 | 2025-07-24 | Takeda Pharmaceutical Company Limited | Improved gip receptor agonist peptide compounds and uses thereof |
| WO2025154021A1 (en) | 2024-01-19 | 2025-07-24 | Takeda Pharmaceutical Company Limited | Improved gip receptor agonist peptide compounds and uses thereof |
| WO2025171340A1 (en) | 2024-02-08 | 2025-08-14 | Aconcagua Bio, Inc. | The treatment of calcitonin- and/or amylin-receptor associated conditions |
Family Cites Families (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2656610B1 (fr) | 1989-12-29 | 1992-05-07 | Sanofi Sa | Derives d'amino-2 phenyl-4 thiazole, leur procede de preparation et leur application therapeutique. |
| CN1221533C (zh) | 1993-09-10 | 2005-10-05 | 卫材株式会社 | 7－氨基－1h－吲哚衍生物 |
| JP3545461B2 (ja) * | 1993-09-10 | 2004-07-21 | エーザイ株式会社 | 二環式ヘテロ環含有スルホンアミド誘導体 |
| CN1072649C (zh) | 1995-09-13 | 2001-10-10 | 武田药品工业株式会社 | 苯并氧杂吖庚因化合物,其生产方法和用途 |
| TR200002447T2 (tr) * | 1998-02-25 | 2000-11-21 | Genetics Institute, Inc. | Fosfolinaz enzimlerinin inhibitörleri |
| JP4007743B2 (ja) | 1999-02-26 | 2007-11-14 | エーザイ・アール・アンド・ディー・マネジメント株式会社 | 血管新生阻害剤 |
| AR035016A1 (es) | 1999-08-25 | 2004-04-14 | Takeda Chemical Industries Ltd | Composicion de azol promotor de produccion/secrecion de neurotrofina, compuesto prodroga del mismo, composicion farmaceutica que lo comprende y uso del mismo para preparar esta ultima. |
| GB0003636D0 (en) * | 2000-02-16 | 2000-04-05 | Smithkline Beecham Plc | Novel compounds |
| AU2001252596A1 (en) | 2000-04-28 | 2001-11-12 | Takeda Chemical Industries Ltd. | Melanin concentrating hormone antagonists |
| WO2001087834A1 (en) | 2000-05-16 | 2001-11-22 | Takeda Chemical Industries, Ltd. | Melanin-concentrating hormone antagonist |
| SI1549638T1 (sl) | 2002-10-03 | 2008-02-29 | Hoffmann La Roche | Indol-3-karboksiamidi kot aktivatorji glukokinaze(gk) |
| EP1532980A1 (en) | 2003-11-24 | 2005-05-25 | Novo Nordisk A/S | N-heteroaryl indole carboxamides and analogues thereof, for use as glucokinase activators in the treatment of diabetes |
| US7498445B2 (en) * | 2004-05-05 | 2009-03-03 | Renopharm Ltd. | Thiazole-based nitric oxide donors capable of releasing two or more nitric oxide molecules and uses thereof |
| EP1632491A1 (en) * | 2004-08-30 | 2006-03-08 | Laboratorios Del Dr. Esteve, S.A. | Substituted indole compounds and their use as 5-HT6 receptor modulators |
| EP2308839B1 (en) * | 2005-04-20 | 2017-03-01 | Takeda Pharmaceutical Company Limited | Fused heterocyclic compounds |
| WO2007037543A1 (ja) | 2005-09-29 | 2007-04-05 | Banyu Pharmaceutical Co., Ltd. | ビアリールアミド誘導体 |
| EP1935890B1 (en) | 2005-09-30 | 2016-03-16 | Msd K.K. | 2-heteroaryl-substituted indole derivative |
| UY31293A1 (es) | 2007-08-14 | 2009-03-31 | Pirimidinas biciclicas fusionadas | |
| AU2008288390A1 (en) | 2007-08-14 | 2009-02-19 | Bayer Schering Pharma Aktiengesellschaft | Fused imidazoles for cancer treatment |
| JO2784B1 (en) | 2007-10-18 | 2014-03-15 | شركة جانسين فارماسوتيكا ان. في | 5,3,1 - Triazole substitute derivative |
| WO2009050186A1 (en) | 2007-10-18 | 2009-04-23 | Janssen Pharmaceutica Nv | Trisubstituted 1,2,4-triazoles |
-
2007
- 2007-10-18 MX MX2009003972A patent/MX2009003972A/es active IP Right Grant
- 2007-10-18 JP JP2009515658A patent/JP5260507B2/ja not_active Expired - Fee Related
- 2007-10-18 AU AU2007310064A patent/AU2007310064B2/en not_active Ceased
- 2007-10-18 US US11/907,929 patent/US7652133B2/en not_active Expired - Fee Related
- 2007-10-18 MY MYPI20091549A patent/MY158052A/en unknown
- 2007-10-18 UA UAA200904957A patent/UA97257C2/ru unknown
- 2007-10-18 GE GEAP200711259A patent/GEP20115241B/en unknown
- 2007-10-18 EP EP07830506A patent/EP2074119A1/en not_active Withdrawn
- 2007-10-18 US US12/311,893 patent/US8410087B2/en not_active Expired - Fee Related
- 2007-10-18 CA CA2666973A patent/CA2666973C/en not_active Expired - Fee Related
- 2007-10-18 ME MEP-118/09A patent/MEP11809A/xx unknown
- 2007-10-18 WO PCT/JP2007/070772 patent/WO2008050821A1/en not_active Ceased
- 2007-10-18 TW TW096138971A patent/TWI460176B/zh not_active IP Right Cessation
- 2007-10-18 RU RU2009118602/04A patent/RU2454415C9/ru not_active IP Right Cessation
- 2007-10-18 KR KR1020097010151A patent/KR101444486B1/ko not_active Expired - Fee Related
- 2007-10-18 BR BRPI0717722-4A patent/BRPI0717722A2/pt not_active IP Right Cessation
- 2007-10-18 NZ NZ576570A patent/NZ576570A/en not_active IP Right Cessation
- 2007-10-18 EP EP12170280A patent/EP2508524A3/en not_active Withdrawn
- 2007-10-18 CN CN2007800470664A patent/CN101573357B/zh not_active Expired - Fee Related
- 2007-10-18 ZA ZA200902585A patent/ZA200902585B/xx unknown
-
2008
- 2008-04-10 CL CL2008001017A patent/CL2008001017A1/es unknown
- 2008-04-16 PE PE2008000659A patent/PE20090884A1/es not_active Application Discontinuation
-
2009
- 2009-03-19 US US12/382,622 patent/US7777047B2/en not_active Expired - Fee Related
- 2009-03-19 US US12/382,623 patent/US7718798B2/en not_active Expired - Fee Related
- 2009-04-08 TN TNP2009000129A patent/TN2009000129A1/fr unknown
- 2009-04-16 IL IL198154A patent/IL198154A/en not_active IP Right Cessation
- 2009-04-24 CR CR10748A patent/CR10748A/es unknown
- 2009-05-13 MA MA31871A patent/MA30890B1/fr unknown
- 2009-05-14 EC EC2009009330A patent/ECSP099330A/es unknown
- 2009-05-19 NO NO20091948A patent/NO20091948L/no not_active Application Discontinuation
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ECSP099330A (es) | Compuesto de indol | |
| CR10564A (es) | Compuestos cíclicos fusionados | |
| CO6321240A2 (es) | Compuestos de anillo fusionados como activadores de glucocinasa | |
| MX2010009736A (es) | Compuesto heterociclico. | |
| AR064736A1 (es) | Agonistas de gpcr | |
| DOP2013000118A (es) | Compuesto bicíclico | |
| DOP2010000183A (es) | Derivados de itazol usados como inhibidores de pi 3-cinasa | |
| AR081819A1 (es) | Derivados de pirimidil-piperidinil-oxipiridinona, composiciones farmaceuticas que los contienen y uso de los mismos para tratar diabetes, dislipemias, obesidad y otras enfermedades | |
| CO6251282A2 (es) | Oxazolidinonas sustituidas y su uso | |
| UY31712A1 (es) | Nuevos derivados de diosmetina, su procedimiento de preparacion y las composiciones farmacéuticas que los contienen | |
| NI201100117A (es) | Antagonistas de 4 -- azetidinil - 1 - heteroaril - ciclohexanol del ccr2. | |
| UY31781A (es) | Derivados de iminopiridina y su uso | |
| CL2011003154A1 (es) | Compuestos derivados de pirazinooxazepina, activador del receptor de serotonina 5-ht2c, composicion farmaceutica que los comprende; y su uso en el tratamiento y/o profilaxis de sintomas del aparato urinario inferior, obesidad y/o prolapso de organos. | |
| BR112012013918A2 (pt) | inibidores de diacil glicerol acil transferase | |
| AR061478A1 (es) | Compuesto triciclico y composicion farmaceutica | |
| PA8787001A1 (es) | " derivados de macrolactona" | |
| BRPI0615614A2 (pt) | compostos orgánicos | |
| AR068978A1 (es) | N-oxidos de venlafaxina y o-desmetilvenlafaxina como prodrogas | |
| DOP2009000081A (es) | Compuesto de indol | |
| TN2010000450A1 (en) | Fused ring compounds and use thereof | |
| CR10267A (es) | Agente terapéutico o profiláctico para el síndrome de colon irritable | |
| TN2010000397A1 (en) | Heterocyclic compounds | |
| UY32191A (es) | Derivados de iminopiridina y uso de los mismos |